Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 9/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.37 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10938727 | 0.90 | SMN1; SMN2 (0.39) | OPRM1SMN1; SMN2OPRD1OPRK1SLC22A1 | |
| SCHEMBL10941629 | 0.85 | OPRM1 (0.37) | OPRM1SMN1; SMN2OPRD1OPRK1SLC22A1 | |
| SCHEMBL15129681 | 0.82 | NPSR1 (0.32) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL610749 | 0.82 | POLB (0.38) | OPRM1SMN1; SMN2OPRD1OPRK1SLC22A1 | |
| SCHEMBL19338176 | 0.82 | OPRM1 (0.35) | OPRM1SMN1; SMN2OPRD1OPRK1SLC22A1 | |
| SCHEMBL16841462 | 0.81 | PRMT1 (0.41) | OPRM1SMN1; SMN2OPRD1OPRK1SLC22A1 | |
| SCHEMBL4740320 | 0.78 | POLB (0.35) | OPRM1SMN1; SMN2OPRD1OPRK1SLC22A1 | |
| SCHEMBL15348156 | 0.76 | MEN1 (0.47) | OPRM1SMN1; SMN2OPRK1MEN1KMT2A | |
| SCHEMBL9634363 | 0.76 | — | — | |
| SCHEMBL15166801 | 0.75 | P2RX7 (0.41) | OPRM1SMN1; SMN2OPRD1OPRK1SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230039502-A1 | COMPOUNDS FOR SELECTIVE BINDING TO ESTROGEN RECEPTORS ALPHA/BETA RELATIVE TO GPER/GPR30 AND METHODS OF TREATING DISEASE STATES AND CONDITIONS MEDIATED THROUGH THESE RECEPTORS | UNM RAINFOREST INNOVATIONS | 2023-02-09 | — | — | US | disclosed |
| WO-2021041107-A1 | COMPOUNDS FOR SELECTIVE BINDING TO ESTROGEN RECEPTORS ALPHA/BETA RELATIVE TO GPER/GPR30 | UNM RAINFOREST INNOVATIONS (US) | 2021-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039502-A1 | COMPOUNDS FOR SELECTIVE BINDING TO ESTROGEN RECEPTORS ALPHA/BETA RELATIVE TO GPER/GPR30 AND METHODS OF TREATING DISEASE STATES AND CONDITIONS MEDIATED THROUGH THESE RECEPTORS | GPER1, GPR35, GPR34 | OPRM1 99/4885SMN1; SMN2 1600/4885OPRD1 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.